RAAS antagonists, notably Angiotensin Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs) are extremely beneficial in the control of cardiac and renal pathologies and are considered first-line treatment for uncomplicated HTN, HTN with CHF, previous myocardial infarction (MI), and CKD [62]. Here, ACE is linked to chronic kidney disease.